Sensible Bio lands $47M to scale mRNA manufacturing
What's the deal? Sensible BiotechnologiesDealroom has a profile for this one. Try Dealroom → has raised $47 million in a Series A round to build out its manufacturing platform for mRNA therapeutics. The company plans to stake a claim in a growing corner of biopharma.
Why now? mRNA therapeutics is drawing fresh capital and dealmaking. NovartisDealroom has a profile for this one. Try Dealroom → recently took rights to Abogen's mRNA T cell engager for $575 million upfront, underscoring the heat around the field.
How big is the round? The $47 million Series A ranks among the larger raises of its kind, sitting in roughly the 96th percentile of comparable Series A rounds in its sector and country, based on a sample of more than 2,200 deals.
The signal: With large pharma writing nine-figure cheques for mRNA assets, startups building the manufacturing backbone stand to benefit from rising demand. Sensible's raise suggests investors see value not just in the therapies, but in the tools that make them.
Read more: endpoints.news
Image credit: Sensible Biotechnologies
